Ipsen (CHIX:IPNP) Price-to-Funds-From-Operations: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IPNP Ipsen SA CHIX:IPNP
94 GF Score
Price €158.95
GF Value €134.61
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ipsen Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

CHIX:IPNP
94GF Score
Ipsen SA CHIX:IPNP
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (CHIX:IPNP) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €158.95 is trading 18.1% above its estimated GF Value™ of €134.61. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for CHIX:IPNP:

  • Price-to-Funds-From-Operations:
  • GF Value™: €134.61 vs. price of €158.95 (18.1% above fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the CHIX:IPNP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
94GF Score

Get the complete analysis for CHIX:IPNP

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.95
Price
€134.61
GF Value